UNITED STATES SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 14C
INFORMATION STATEMENT PURSUANT TO SECTION
14(c)
OF THE SECURITIES EXCHANGE ACT OF 1934
Check the appropriate box:
| ¨ | Preliminary
Information Statement |
| ¨ | Confidential,
For Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) |
| x | Definitive
Information Statement |
CYTOCORE,
INC.
(Name of Registrant as Specified in its
Charter)
Payment of Filing Fee (Check
the appropriate box):
| ¨ | Fee
computed on table below per Exchange Act Rules 14c-5(g) and 0-11. |
| (1) | Title
of each class of securities to which transaction applies: |
| (2) | Aggregate
number of securities to which transaction applies: |
| (3) | Per
unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which
the filing fee is calculated and state how it was determined): |
| (4) | Proposed
maximum aggregate value of transaction: |
| ¨ | Fee
paid previously with preliminary materials. |
| ¨ | Check
box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting
fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of
its filing. |
| (1) | Amount
Previously Paid: |
| (2) | Form,
Schedule or Registration Statement No.: |
CYTOCORE, INC.
4303 SW 34th St.
Orlando FL 32811
(407) 996-9631
Dear Stockholder:
This Information Statement
is being furnished on or about October 9, 2014, by Cytocore, Inc., a Delaware corporation (the “Company”), to holders
of the Company’s outstanding common stock, par value $0.001 per share (“Common Stock”), as of the close of business
on September 26, 2014, pursuant to Rule 14c−2 under the Securities Exchange Act of 1934, as amended (the “Exchange
Act”). The purpose of this Information Statement is:
(i) to inform you that
we have obtained the written consent of the holder of the majority of the issued and outstanding shares of our Common Stock to
amend our certificate of incorporation to increase the number of shares of Common Stock that we are authorized to issue from 2,000,000,000
to 3,500,000,000 in the discretion of our board of directors; and
(ii) to serve as notice
of the foregoing actions in accordance with Section 228(e) of the Delaware General Corporation Law.
The holder of the majority
of our issued and outstanding shares of Common Stock executed a written consent in favor of the foregoing action on September 26,
2014. This consent satisfied the stockholder approval requirements under Delaware law and our certificate of incorporation and
will allow us to take the proposed action as soon as practicable.
WE ARE NOT ASKING
YOU FOR A PROXY AND YOU ARE REQUESTED NOT TO SEND US A PROXY. Your consent to the aforementioned action is not required and
is not being solicited. The accompanying Information Statement is being furnished to you for informational purposes only. Please
read the accompanying Information Statement carefully.
| |
/s/ Michaela Ott. |
| |
Michaela Ott |
| |
Chief Executive Officer |
| |
|
October 9, 2014
|
|
_____________________________
CYTOCORE, INC.
4303 SW 34th St.
Orlando FL 32811
(407) 996-9631
______________________________
INFORMATION STATEMENT
Dated October 9, 2014
WE ARE NOT ASKING YOU FOR A PROXY AND
YOU ARE REQUESTED NOT TO SEND US A PROXY
INTRODUCTION
This Information Statement
is being mailed on or about October 9, 2014 to the stockholders of record of Cytocore, Inc. (the “Company,” “we”
or “us”) at the close of business on September 26, 2014 (the “Record Date”). This Information Statement
is being sent to you for information purposes only. No action is required or requested on your part.
This Information Statement
is being provided:
(i) to
inform you that we have obtained the written consent of the holder of the majority of the issued and outstanding shares of our
Common Stock to amend our certificate of incorporation to increase the number of shares of Common Stock that we are authorized
to issue from 2,000,000,000 to 3,500,000,000 in the discretion of our board of directors; and
(ii) to
serve as notice of the foregoing actions in accordance with Section 228(e) of the Delaware General Corporation Law.
Section 228(a) of the
Delaware General Corporation Law states that, unless otherwise provided in the certificate of incorporation, any action that may
be taken at any annual or special meeting of stockholders may be taken without a meeting, without prior notice and without a vote,
if consents in writing, setting forth the action so taken, are signed by the holders of outstanding stock having not less than
the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled
to vote thereon were present and voted, and those consents are delivered to the corporation by delivery to its registered office
in Delaware, its principal place of business, or an officer or agent of the corporation having custody of the book in which proceedings
of meetings of stockholders are recorded.
The amendment was approved
on September 26, 2014, upon the execution of a written consent by the holders of the majority of the issued and outstanding shares
of our Common Stock. Because the amendment has been approved by the holders of the requisite number of outstanding shares that
are entitled to cast votes, no other stockholder approval of the amendment is necessary. This Information Statement will also serve
as notice of actions taken without a meeting as required by Section 228(e) of the Delaware General Corporation Law. No further
notice of the actions described herein will be given to you.
We
are currently authorized to issue 2,000,000,000 shares of Common Stock and 10,000,000 shares of preferred stock, $.001 par value
per share (“Preferred Stock”). As of the close of business on the Record Date, there were 1,926,795,621
shares of Common Stock, 47,250 shares of Series A Convertible Preferred Stock, 93,750 shares of Series B Convertible
Preferred Stock, 38,333 shares of Series C Convertible Preferred Stock, 175,000 shares of Series D Convertible Preferred Stock,
and 19,022 shares of Series E Stock issued and outstanding. Each share of Common Stock is entitled to one vote. The affirmative
vote or written consent of the holders of a majority of the issued and outstanding shares of our Common Stock is necessary to approve
the amendment to our certificate of incorporation. The requisite stockholder approval of the amendments was obtained on September
26, 2014.
The expenses of preparing
and mailing this Information Statement and all documents that now accompany or may hereafter supplement it will be borne by us.
We will reimburse brokers and other persons holding stock in their names or the names of nominees for their expenses incurred in
forwarding this Information Statement to the beneficial owners of such shares.
Amendment
to our CERTIFICATE of Incorporation to INCREASE the NUMBER OF SHARES OF COMMON STOCK AVAILABLE FOR ISSUANCE
Background
In order to ensure
that we have sufficient authorized shares to execute our business plan, on September 26, 2014, our board of directors executed
a written consent authorizing the amendment to our certificate of incorporation to increase the number of shares of Common Stock
that we are authorized to issue from 2,000,000,000 to 3,500,000,000. On September 26, 2014, the holders of the majority of the issued
and outstanding shares of our Common Stock and Series E Convertible Preferred Stock, voting together as a single class, acted
by written consent to authorize our board of directors to effect the amendment in its discretion. Our board of directors intends
to implement the amendment to our certificate of incorporation to increase the number of shares that we are authorized to issue.
A copy of this amendment
is attached to this Information Statement as Appendix A (subject to any changes required by applicable law) (the “Certificate
of Amendment”).
Reasons for the Amendment
The
reason for the amendment to our certificate of incorporation to increase the number of shares of Common Stock that we are authorized
to issue is to provide us with the ability to support our present capital needs and future anticipated growth. As of September
26, 2014, 1,926,795,621 shares of Common Stock were authorized
but unissued and available for issuance, which may not be sufficient to meet our capital needs. The availability of additional
shares of Common Stock would also provide us with the flexibility to consider and respond to future business opportunities and
needs as they arise, including equity offerings, mergers or other business combinations, asset acquisitions, stock dividends, stock
splits and other corporate purposes. The Company currently has no agreements for any of the foregoing.
The additional shares
of Common Stock would have rights identical to our Common Stock currently outstanding. Approval of the proposed amendment and any
issuance of Common Stock would not affect the rights of the holders of our Common Stock currently outstanding, except for the effects
incidental to increasing the outstanding number of shares of Common Stock, such as dilution of earnings per share, if any, and
voting rights of current holders of our Common Stock.
If authorized, the additional shares of
Common Stock may be issued with approval of our board of directors, but without further approval of our stockholders, unless stockholder
approval is required by applicable law, rule or regulation. Under our certificate of incorporation, the holders of our Common Stock
do not have preemptive rights with respect to future issuances of Common Stock. Thus, should our board of directors elect to issue
additional shares of Common Stock, our existing stockholders will not have any preferential rights to purchase such shares and
such issuance could have a dilutive effect on the voting power and percentage ownership of these stockholders. The issuance of
additional shares of Common Stock could also have a dilutive effect on our earnings per share, if any.
Anti-Takeover and Dilutive Effects
The purpose of increasing
the number of shares of Common Stock that we are authorized to issue from 2,000,000,000 to 3,500,000,000 is to facilitate our
ability to raise additional capital to support our operations, not to establish any barriers to a change of control or acquisition
of the Company. Shares of Common Stock that are authorized but unissued provide our board of directors with flexibility to effect,
among other transactions, public or private financings, subscription rights offerings, mergers, acquisitions, stock dividends,
stock splits and the granting of equity incentive awards. However, these authorized but unissued shares may also be used by our
board of directors, consistent with and subject to its fiduciary duties, to deter future attempts to gain control of us or make
such actions more expensive and less desirable.
In addition, the issuance
of additional shares of Common Stock for any of the corporate purposes listed above could have a dilutive effect on earnings per
share and the book or market value of the outstanding Common Stock, depending on the circumstances, and would likely dilute a stockholder's
percentage voting power in the Company. Holders of Common Stock are not entitled to preemptive rights or other protections against
dilution.
We did not propose
this amendment to our certificate of incorporation in response to any effort known to us to accumulate Common Stock or to obtain
control of us by means of a merger, tender offer or solicitation in opposition to management.
Procedure for Effecting the Certificate of Amendment
We will affect the
increase in authorized shares by filing the Certificate of Amendment with the Secretary of State of the State of Delaware. The
increase in authorized shares will become effective at the time of the filing of the Certificate of Amendment (referred to as the
"effective time") without any action on the part of our stockholders The text of the Certificate of Amendment is subject
to modification to include such changes as may be required by the office of the Secretary of State of the State of Delaware and
as our board of directors deems necessary and advisable to effect the increase in authorized shares.
Our board of directors
reserves the right, notwithstanding stockholder approval and without further action by the stockholders, to elect not to proceed
with the increase in authorized shares if, at any time prior to filing the Certificate of Amendment, our board of directors, in
its sole discretion, determines that it is no longer in the best interests of the Company and its stockholders to proceed with
the increase in authorized shares.
Effective Date of the Amendment
The amendment to our
Certificate of Incorporation will become effective upon the filing of a Certificate of Amendment to our certificate of incorporation
with the Secretary of State of Delaware. Our board of directors intends to file the Certificate of Amendment as soon as practicable
upon the passing of 20 calendar days from the date a definitive copy of this Information Statement is mailed to our stockholders.
The full text of the proposed amendment is set forth in Appendix A to this Information Statement. The text of the amendment
is subject to modification to include such changes as may be required by the office of the Secretary of State of Delaware and as
our board of directors deems necessary and advisable to effect the amendment.
Required Vote
The affirmative vote
or written consent of the holders of a majority of the issued and outstanding shares of our Common Stock is necessary to approve
the amendment to our Certificate of Incorporation. The requisite stockholder approval of the amendments was obtained on September
26, 2014.
Notice of Action by Written Consent
Pursuant to Rule 14c-2
of Regulation 14C promulgated under the Exchange Act, we are required to distribute an information statement to every stockholder
from whom consent is not solicited at least 20 calendar days prior to the earliest date on which the proposed amendment to our
certificate of incorporation becomes effective. This Information Statement serves as the notice required by Rule 14c-2 of Regulation
14C.
Dissenters’ Rights
The stockholders have
no right under the DGCL, the Company’s certificate of incorporation consistent with above, or the Company’s bylaws
to dissent from the action adopted as set forth herein.
Beneficial
Ownership of OUR Common Stock
The following table
sets forth certain information, as of September 26, 2014 with respect to holdings of our Common Stock by (i) each person known
by us to be the beneficial owner of more than 5% of the total number of shares of Common Stock outstanding as of such date, (ii)
each of our directors and executive officers, and (iii) all directors and executive officers as a group. Except as otherwise indicated,
the address of each person is c/o Cytocore, Inc.,4203 SW 34th St., Orlando, FL 32811.
| Name and Address of Beneficial Owner | |
Beneficial Ownership(1) | | |
of Class | |
| | |
| | |
| |
| Michaela Ott | |
| 1,468,750,000 | (2) | |
| 77.1 | % |
| | |
| | | |
| | |
| Michael Ott | |
| 1,468,750,000 | (3) | |
| 77.1 | % |
| | |
| | | |
| | |
| Robert F. McCullough | |
| 167,690,706 | (4) | |
| 8.8 | % |
| | |
| | | |
| | |
| Augusto Ocana | |
| 9,090,835 | | |
| * | |
| | |
| | | |
| | |
| Mauro Scimia | |
| 5,959,750 | | |
| * | |
| | |
| | | |
| | |
| John H. Abeles, M.D. | |
| 12,625,598 | (5) | |
| * | |
| | |
| | | |
| | |
| Alexander M. Milley | |
| 4,652,950 | (6) | |
| * | |
| | |
| | | |
| | |
| Xavier Carbonell | |
| 6,569,823 | | |
| * | |
| | |
| | | |
| | |
| All current directors and executive officers as a group (8 persons) | |
| 1,675,339,662 | | |
| 88.0 | % |
| (1) | Unless
otherwise indicated, each of the persons named in the table has sole voting and investment power with respect to the shares set
forth opposite such person’s name. With respect to each person or group, percentages are calculated based on the number
of shares beneficially owned, including shares that may be acquired by such person or group within 60 days of September 26, 2014
upon the exercise of stock options, warrants or other purchase rights, but not the exercise of options, warrants or other purchase
rights held by any other person. There were 1,926,795,621 shares
of common stock outstanding as of the close of business on September 26, 2014. |
| (2) | Includes:
(i) 734,375,000 shares held by Mrs. Ott’s husband, Michael Ott, and (ii) 187,500,000 shares currently being held in escrow
in order to satisfy certain indemnification obligations of Mrs. Ott in connection with the acquisition of Medite. |
| (3) | Includes:
(i) 734,375,000 shares held by Mr. Ott’s wife, Michaela Ott, and (ii) 187,500,000 shares currently being held in escrow
in order to satisfy certain indemnification obligations of Mr. Ott in connection with the acquisition of Medite. |
| (4) | Includes
an aggregate 166,205 shares owned by various trusts of which Mr. McCullough is trustee as follows: MJM Educational Trust (15,000)
shares, PFM Educational Trust (15,000 shares), CDM Educational Trust (15,000) shares and the MPC Trust (121,205 shares). |
| (5) | Includes:
(i) 6,775,598 shares owned by Northlea Partners, Ltd., of which Dr. Abeles is General Partner; and (ii) 100,000 shares of common
stock awarded in 2009 that have not yet been issued. Dr. Abeles disclaims beneficial ownership of all shares owned by, or
issuable to, Northlea Partners except shares attributable to his 1% interest in Northlea Partners as General Partner. |
| (6) | Includes:
(i) 149,551 shares held by Azimuth Corporation, of which Mr. Milley is President and Chairman of the Board of Directors, 429,255
shares held by Cadmus Corporation, of which Mr. Milley is President and a director, 80,282 shares held by Milley Management, Inc.,
of which Mr. Milley is President, sole director and majority stockholder, and 23,710 shares held by Winchester National, Inc.,
of which Mr. Milley is a director and executive officer; and (ii) 100,000 shares of common stock awarded in 2009 that have not
yet been issued. An aggregate of 402,890 shares of common stock held directly by Mr. Milley, Cadmus Corporation, Winchester
National and Milley Management have been pledged to ELXSI Corp., of which Mr. Milley is President, Chief Executive Officer and
Chairman of the Board. |
Change In Control Transaction in Last Fiscal Year.
We are not aware of any arrangements (including
any pledge by any person of our securities), the operation of which did or may at a subsequent date result in a change of control.
HOUSEHOLDING
Under SEC rules, only
one annual report, information statement or Notice of Internet Availability of Proxy Materials, as applicable, need be sent to
any household at which two or more of our stockholders reside if they appear to be members of the same family and contrary instructions
have not been received from an affected stockholder. This procedure, referred to as householding, reduces the volume of duplicate
information stockholders receive and reduces mailing and printing expenses for us. Brokers with accountholders who are our stockholders
may be householding these materials. Once you have received notice from your broker that it will be householding communications
to your address, householding will continue until you are notified otherwise or until you revoke your consent. If, now or at any
time in the future, you no longer wish to participate in householding and would like to receive a separate annual report, information
statement or Notice of Internet Availability of Proxy Materials, or if you currently receive multiple copies of these documents
at your address and would prefer that the communications be householded, you should contact us at 4203 SW 34th St,, Orlando, FL
32811or (407) 996-9631.
REQUESTS FOR CERTAIN DOCUMENTS
We file annual, quarterly
and current reports, proxy statements and other information with the Securities and Exchange Commission (the “SEC”).
You may read and copy any document we file with the SEC at the SEC’s public reference room at 100 F Street, NE, Washington,
DC 20549. Please call the SEC at 1-800-SEC-0330 for information on the public reference room. The SEC maintains an internet site
that contains annual, quarterly and current reports, proxy and information statements and other information that issuers (including
us) file electronically with the SEC. Our electronic SEC filings are available to the public at the SEC’s internet site,
www.sec.gov.
We make available free
of charge financial information, news releases, SEC filings, including our annual report on Form 10-K, quarterly reports on Form
10-Q, current reports on Form 8-K and amendments to these reports as soon as reasonably practical after we electronically file
such material with, or furnish it to, the SEC, on our website at www.globalstar.com. The documents available on and the contents
of, our website are not incorporated by reference into this Information Statement.
| |
/s/ Michaela Ott. |
| |
Michaela Ott |
| |
Chief Executive Officer |
| |
|
Dated: October 9, 2014
|
|
Appendix A
CERTIFICATE OF AMENDMENT
TO THE
CERTIFICATE OF INCORPORATION
OF
CYTOCORE, INC.
Pursuant to Section 242 of the
General Corporation Law of the State
of Delaware
CytoCore, Inc., a Delaware
corporation (the “Corporation”), does hereby certify as follows:
1. The
Board of Directors of the Corporation (the “Board”), acting by Unanimous Written Consent in accordance with Section
141(f) of the General Corporation Law of the State of Delaware (the “DGCL”) adopted a resolution authorizing the Corporation
to increase the number of shares of the common stock, $.001 par value per share (the “Common Stock”) that the Corporation
is authorized to issue from 2,000,000,000 to 3,500,000,000 and to file this Certificate of Amendment:
Article
FOURTH of the Certificate of Incorporation shall be amended by deleting Section 4.1 in its entirety and submitting therefor the
following:
“Section
4.1. The total number of shares of stock which the Corporation is authorized to issue is Three Billion Five Hundred Ten Million
(3,510,000,000) shares, comprised of Three Billion Five Hundred Million (3,500,000,000) shares of common stock, par value $0.001
per share, and Ten Million (10,000,000) shares of preferred stock, par value $0.001 per share.”
2. That
in lieu of a meeting and vote of stockholders, the holders of a majority in interest of record of the issued and outstanding shares
of Common Stock have given written consent to said amendment in accordance with the provisions of Section 228 of the DGCL.
3. That
the aforesaid amendment was duly adopted in accordance with the applicable provisions of Section 242 of the DGCL.
IN WITNESS WHEREOF, CytoCore, Inc. has
caused this Certificate of Amendment to be duly executed in its corporate name this 9th day of October, 2014.
CYTOCORE, INC.
| By: |
/s/ Micheala Ott |
|
| |
Chief Executive Officer |
|
Himalaya Technologies (PK) (USOTC:HMLA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Himalaya Technologies (PK) (USOTC:HMLA)
Historical Stock Chart
From Apr 2023 to Apr 2024
